Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
Journal of the Royal Medical Services. 2013; 20 (2): 45-50
in English | IMEMR | ID: emr-138395

ABSTRACT

To evaluate the effect of olopatadine 0.1% ophthalmic solution twice daily on ocular and nasal symptoms in patients with seasonal allergic rhino-conjunctivitis. This study was conducted at the Ophthalmology and ear, nose and throat [ENT] clinics on patients with seasonal allergic rhino-conjunctivitis during spring and early summer seasons [March to end of June] in 2010 at Princess Haya Al Hussein hospital in the south of Jordan and in 2011 at Prince Rashid Bin Al Hassan hospital in the north of Jordan. The patients were divided randomly into 2 groups; group A [50 patients] received Olopatadine 0.1% ophthalmic solution [Patanol] twice daily, group B [51 patients] received placebo in the form of balanced salt solution. All patients attended ENT and Ophthalmology clinics weekly for 2 visits; they were reviewed regarding the improvement of ocular symptoms [itching, redness and lacrimation] and nasal symptoms [sneezing, itchy nose and runny nose]. In those patients who received Olopatadine 0.1% ophthalmic solution, after two weeks 98%, 98% and 90% of them showed satisfactory improvement according to a scale of 1 to 5 marked by the patients for itching, lacrimation and redness respectively compared to 14%, 12% and 6% in group B respectively [P-value <0.05]. Regarding nasal symptoms 90%, 84% and 78% of patients in group A showed satisfactory improvement regarding sneezing, running nose and nasal itching respectively compared to 8%, 16% and 10% in group B [P-value <0.05]. The treatment of ocular allergy positively impacts nasal symptoms. The use of ocular solution of Olopatadine 0.1% ophthalmic solution twice daily has an excellent effect on ocular symptoms and good effect on nasal symptoms, this effect was more significant at two weeks of treatment. Olopatadine 0.1% ophthalmic solution is a well-tolerated drug and may be considered as a primary treatment for patients with seasonal allergic rhino-conjunctivitis


Subject(s)
Humans , Female , Male , Conjunctivitis/drug therapy , Rhinitis, Allergic, Seasonal/drug therapy , Anti-Inflammatory Agents, Non-Steroidal , Ophthalmic Solutions , Anti-Allergic Agents , Hypersensitivity/drug therapy , Ophthalmology , Treatment Outcome
2.
Pakistan Oral and Dental Journal. 2013; 33 (2): 281-282
in English | IMEMR | ID: emr-147827

ABSTRACT

Tumors of the sub mandibular salivary glands are rare, comprising less than 2% of head and neck neoplasms. The purpose of this study was to report and evaluate submandibular salivary gland neoplasms related to the current study. A retrospective review of database of patients who underwent surgery for submandibular salivary gland neoplasms in the department of oral and maxillofacial surgery at King Hussein medical center, Amman- Jordan during the last twelve years period was performed. Patients were analyzed according to age, sex and histopathological examination. Twenty eight patients formad the study group [11 males, 17 females] with a mean age of 34.6 years. Twenty three patients [82%] were benign [mostly pleomorphic adenomas] and five [18%] were of malignant type. Benign tumors appeared in younger patients

SELECTION OF CITATIONS
SEARCH DETAIL